CONFIG2: Saphenous Vein as Y-composite Versus Aortocoronary Conduit for CABG

Sponsor
Ho Young Hwang (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05704296
Collaborator
(none)
290
1
2
60
4.8

Study Details

Study Description

Brief Summary

Left internal thoracic artery (LITA) has been acknowledged as the first graft of choice for coronary artery bypass grafting (CABG). However, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for CABG.

In our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'No touch technique'. We have been demonstrated the excellent long-term patency of this 'No touch saphenous vein' in many studies. However, it is still unknown which configuration is the better strategy for the saphenous vein as a Y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. Thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (IVUS) study and angiographic patency results between Y-composite graft and aortocoronary conduit.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Y-composite grafting
  • Procedure: Aortocoronary grafting
N/A

Detailed Description

The enrolled patient underwent routine sternotomy, and left internal thoracic artery (LITA) and saphenous vein (SV) are harvested. After harvest, the patient is randomized to Y-composite group or aortocoronary group.

For Y-composite group, SV is anastomosed to LITA as Y-composite fashion. Then, LITA is anastomosed to left anterior descending artery. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posterior descending artery).

For aortocoronary group, LITA is anastomosed to left anterior descending artery. Then, SV is anastomosed to ascending aorta using proximal anastomosis assist device without clamping the aorta. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery).

At 1-year follow-up, coronary angiography is performed to evaluate the patency of the saphenous vein graft. Clinical outcomes are also evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
290 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Saphenous vein as Y-composite graft based on the left internal thoracic artery versus aortocoronary conduitSaphenous vein as Y-composite graft based on the left internal thoracic artery versus aortocoronary conduit
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison Between the Saphenous Vein as Y-composite Graft Based on the Left Internal Thoracic Artery Versus Aortocoronary Conduit for Coronary Artery Bypass Grafting: A Prospective Randomized Controlled Trial
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2027
Anticipated Study Completion Date :
Jan 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Y-composite grafting

The saphenous vein is anastomosed to the middle portion of the left internal thoracic artery as Y-composite fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.

Procedure: Y-composite grafting
Saphenous vein is used as a Y-composite graft during coronary artery bypass grafting

Active Comparator: Aortocoronary grafting

The saphenous vein is anastomosed to the ascending aorta as aortocoronary fashion. Then, left anterior descending artery, if targeted, is bypassed with left internal thoracic artery. Other native coronary arterial targets are bypassed with saphenous vein graft.

Procedure: Aortocoronary grafting
Saphenous vein is used as an aortocoronary graft during coronary artery bypass grafting

Outcome Measures

Primary Outcome Measures

  1. Graft patency [at postoperative 1 year]

    Graft patency measured by coronary angiography

Secondary Outcome Measures

  1. All-cause mortality [at postoperative 1 year]

    all deaths from any cause

  2. Cardiac death [at postoperative 1 year]

    Any death related to cardiac events, including sudden death during follow-up

  3. Target vessel revascularization [at postoperative 1 year]

    Intervention performed for the previously bypassed target vessel during follow-up

  4. Reintervention [at postoperative 1 year]

    Any coronary intervention performed during follow-up due to the coronary artery disease

  5. Major Adverse Cardiac Events (MACEs) [at postoperative 1 year]

    acute myocardial infarction, coronary reintervention, and cardiac death including sudden death during follow-up

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A patient who is going to receive coronary artery bypass grafting

  • Older than 19 years

  • Coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft

Exclusion Criteria:
  • Other concomitant procedures (e.g. valve or aorta surgery) is planned

  • Patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer)

  • Patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft

  • Patients whose ascending aorta is not suitable to aortocoronary anastomosis (e.g. ascending aorta aneurysm, porcelain aorta)

  • Emergency operation

  • Patients who have connective tissue disease

  • Reoperative coronary artery bypass grafting

Contacts and Locations

Locations

Site City State Country Postal Code
1 Seoul National University Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Ho Young Hwang

Investigators

  • Principal Investigator: Ho Young Hwang, MD, PhD, Seoul National University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ho Young Hwang, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT05704296
Other Study ID Numbers:
  • H-2211-023-1376
First Posted:
Jan 30, 2023
Last Update Posted:
Feb 3, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ho Young Hwang, Professor, Seoul National University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2023